CTLA‐4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
CTLA‐4 is a co‐receptor that modulates the threshold of T cell activation and autoimmunity. We previously showed that CTLA‐4 reverses the TCR‐mediated stop signal needed for T cell/APC interactions [Schneider et al., Science 2006, 313: 1972]. In this study, using a different T cell system, we show that CTLA‐4 expression changed the behavior of T8.1 T cells by reducing the contact time between T cell and APC, preventing re‐inforced contacts, and reducing the contact area at the immunological synapse. This led to a major reduction in Ca 2+ influx/mobilization and interleukin‐2 production. Further, anti‐CD3/CTLA‐4 increased T cell motility on antibody‐coated glass slides, concurrent with an abrogation of ZAP70 microcluster formation. Our findings further support a role for CTLA‐4 in limiting the interaction between T cell and APC that is needed for optimal activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CTLA4 disrupted the ZAP70 cluster formation in most T cells, although 5%‐10% of T cells demonstrated cluster forming followed by anti‐CD3 treatment [302, 303, 304].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [302]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Varma, R., Campi, G., Yokosuka, T., Saito, T., & Dustin, M. L. (2006) · Immunity · doi:10.1016/j.immuni.2006.04.010 · Cited by 879
Yokosuka, T., Sakata-Sogawa, K., Kobayashi, W., Hiroshima, M., Hashimoto-Tane, A., Tokunaga, M., Dustin, M. L., & Saito, T. (2005) · Nature Immunology · doi:10.1038/ni1272 · Cited by 698
Molecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
T cell receptor ligation induces the formation of dynamically regulated signaling assemblies
Bunnell, S. C., Hong, D. I., Kardon, J. R., Yamazaki, T., McGlade, C. J., Barr, V. A., & Samelson, L. E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203043 · Cited by 632
Cited by
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Self-citationThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
“The expression of CTLA4 has also been shown to affect the formation of microclusters containing ζ-chain-associated protein kinase of 70 kDa (ZAP70”
BackgroundCoinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
“Several other mechanisms have also been reported, including inhibition of microclusters and activation of E3 ligases (Chattopadhyay and Shevach, 2013; Schneider et al., 2008).”
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
“CTLA-4 interferes with the formation of lipid rafts, TCR:ZAP70 microclusters, and the central supramolecular activation complex, each of which plays important roles in T cell activation [85–88].”
BackgroundConfusing signals: Recent progress in CTLA-4 biology
Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 361
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
Molecular and Cellular Functions of CTLA-4
Van Coillie, S., Wiernicki, B., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 243
Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
“Alternatively, several T cell surface molecules have been proposed to actively inhibit antigen-induced stopping and promote T cell motility, including CTLA4 (Downey et al., 2008; Schneider et al., 2006, 2008) and PD-1 (Fife et al., 2009; Schreiber et al., 2010).”
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
“hybridoma that was transfected with human CTLA-4 (96).”
BackgroundTregs: Where We Are and What Comes Next?
Zhao, H., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 196
“Many molecules get involved in CTLA-4-mediated downstream signaling pathway in T cells, including CD3ζ chains (109), ZAP-70 (110), phosphoinositide 3-kinase (111), AKT (protein kinase B) (112) and protein kinase C isoform (113), etc.”
BackgroundEvolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X., & Li, B. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490025 · Cited by 179
What did we learn from CTLA‐4 insufficiency on the human immune system?
Mitsuiki, N., Schwab, C., & Grimbacher, B. (2019) · Immunological Reviews · doi:10.1111/imr.12721 · Cited by 177
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 162
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 172
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Brunner-Weinzierl, M. C., & Rudd, C. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02737 · Cited by 153
“Similarly, the expression of CTLA4 in transformed cell line, Jurkat promotes its motility (63).”
BackgroundSelf-citationThe Immunological Synapse, TCR Microclusters, and T Cell Activation
Yokosuka, T., & Saito, T. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-03858-7_5 · Cited by 149
The reverse stop-signal model for CTLA4 function
Rudd, C. E. (2008) · Nature reviews. Immunology · doi:10.1038/nri2253 · Cited by 155
Self-citationDynamics of Subsynaptic Vesicles and Surface Microclusters at the Immunological Synapse
Purbhoo, M. A., Liu, H., Oddos, S., Owen, D. M., Neil, M. A. A., Pageon, S. V., French, P. M. W., Rudd, C. E., & Davis, D. M. (2010) · Science Signaling · doi:10.1126/scisignal.2000645 · Cited by 136
“Similarly, negative signaling upon the ligation of CTLA-4 inhibits the clustering of ZAP-70 (30), which indicates that the actions of inhibitory receptors on T cells may generally act upstream of the formation of protein microclusters.”
BackgroundSelf-citationKim, G., & Choi, J. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.2056 · Cited by 141
“CTLA-4 agonistic Ab engagement in mouse CD4+ T cells inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), activator protein-1 (AP-1) (Olsson et al., 1999) and cluster formation of zeta chain associated protein kinase 70 (ZAP-70) (Schneider et al., 2008), which are downstream molecules of TC…”
BackgroundRaab, M., Wang, H., Lu, Y., Smith, X., Wu, Z., Strebhardt, K., Ladbury, J. E., & Rudd, C. E. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.007 · Cited by 112
“Cells transfected with RapL-CFP, SKAP1-GFP, and Rap1V12-mcherry were seeded on coverslips with immobilized anti-CD3 and ICAM-1 and imaged at the contact area by confocal microscopy (Bunnell et al., 2002; Schneider et al., 2008).”
MethodSelf-citationCardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 108
Mechanisms and functions for the duration of intercellular contacts made by lymphocytes
Davis, D. M. (2009) · Nature reviews. Immunology · doi:10.1038/nri2602 · Cited by 119
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 115
Waight, J. D., Chand, D., Dietrich, S., Gombos, R., Horn, T., Gonzalez, A. M., Manrique, M., Swiech, L., Morin, B., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 104
CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 112
“It suggests that a role for CTLA-4 in limiting the interaction between T cell and APC that is needed for optimal activation [111].”
BackgroundExpression of checkpoint molecules on myeloid-derived suppressor cells
Ballbach, M., Dannert, A., Singh, A., Siegmund, D. M., Handgretinger, R., Piali, L., Rieber, N. P., & Hartl, D. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.10.001 · Cited by 106
CTLA-4 (CD152): A versatile receptor for immune-based therapy
Lingel, H., & Brunner-Weinzierl, M. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101298 · Cited by 80
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 70
Noncoding RNAs: the shot callers in tumor immune escape
Liu, L., Wang, Q., Qiu, Z., Kang, Y., Liu, J., Ning, S., Yin, Y., Pang, D., & Xu, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0194-y · Cited by 70
“4).(150) Therefore, overexpression of CTLA-4 on the surface of tumor-infiltrating T cells will enhance immune suppression by inhibiting the activation and function of T cells and promoting T cell apoptosis, thus helping tumor cells achieve TIE.”
BackgroundDiverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 74
“Significantly, anti-CTLA-4 alone was able to induce motility of primary T-cells and cell lines (58, 88).”
BackgroundSelf-citationThe Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance
McGrath, M. M., & Najafian, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00047 · Cited by 67
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition
Brzostek, J., Gascoigne, N. R. J., & Rybakin, V. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00024 · Cited by 71
“CTLA-4 ligation has also been reported to reduce the size of T cell: APC contact interface and to reduce ZAP70 microcluster formation (143).”
BackgroundPatsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 60
“CTLA-4 interferes with the formation of lipid rafts, TCR:ZAP70 microclusters, and the central supramolecular activation complex, each of which plays important roles in T cell activation (89, 95, 96).”
BackgroundThe Genetic Basis of Graves Disease
Płoski, R., Szymanski, K., & Bednarczuk, T. (2011) · Current Genomics · doi:10.2174/138920211798120772 · Cited by 59
“CTLA-4 acts by delivering an inhibitory signal through its cytoplasmatic domain which can reverse the classic TCRinduced stop signal needed for physical interaction between T cell and APC, thus reducing adhesion periods between these cells which in turn decreases cytokine production and proliferation [87-89].”
BackgroundImmune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Kim, E. S., Kim, J. E., Patel, M. A., Mangraviti, A., Ruzevick, J., & Lim, M. K. (2016) · Journal of Immunology Research · doi:10.1155/2016/4683607 · Cited by 57
“Downstream effects of the proposed signaling cascades (see Figure 3) may include inhibition of metabolism [31, 32], inactivation of transcription factors [33, 34], inhibition of CD28-mediated lipid raft formation, [35, 36], and loss of calcium mobilization required for cell proliferation [37].”
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 58
“However, CTLA-4 does not interfere directly with ZAP-70 recruitment or phosphorylation [19,20].”
BackgroundLu, Y., Schneider, H., & Rudd, C. E. (2012) · Blood · doi:10.1182/blood-2012-04-421420 · Cited by 47
Self-citationThe immunological synapse: the gateway to the HIV reservoir
Kulpa, D. A., Brehm, J. H., Fromentin, R., Cooper, A. B., Cooper, C., Ahlers, J. D., Chomont, N., & Sékaly, R. (2013) · Immunological Reviews · doi:10.1111/imr.12080 · Cited by 46
“This greatly reduces the contact area at the immunological synapse that leads to a major reduction in Ca mobilization and IL-2 production (122, 123) and could also lead to significant inhibition of HIV replication.”
BackgroundCTLA‐4 co‐receptor impacts on the function of Treg and CD8+ T‐cell subsets
Rudd, C. E. (2009) · European Journal of Immunology · doi:10.1002/eji.200939261 · Cited by 47
Self-citationCurrent and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
“The downstream signaling of CTLA-4 involves the induction of NF-κ B, AP-1, and clustering of zeta chain-associated protein kinase 70 (ZAP-70), which are key molecules in TCR signaling pathways [117].”
BackgroundSzostak, B., Machaj, F., Rosik, J., & Pawlik, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559297 · Cited by 38
CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer
Dehbokri, S. G., Alizadeh, N., Isazadeh, A., Baghbanzadeh, A., Abbaspour‐Ravasjani, S., Hajiasgharzadeh, K., & Baradaran, B. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220610094716 · Cited by 39
Banton, M. C., Inder, K. L., Valk, E., Rudd, C. E., & Schneider, H. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01331-13 · Cited by 35
“(4), disruption of CD28 localization at the immunological synapse”
Self-citationCD152 (CTLA‐4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin
Hegel, J. K., Knieke, K., Kolar, P., Reiner, S. L., & Brunner-Weinzierl, M. C. (2009) · European Journal of Immunology · doi:10.1002/eji.200838770 · Cited by 40
CD28–CD80 Interactions Control Regulatory T Cell Motility and Immunological Synapse Formation
Thauland, T. J., Koguchi, Y., Dustin, M. L., & Parker, D. C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401752 · Cited by 36
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
Freitas, C. M. T., Johnson, D. K., & Weber, K. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051295 · Cited by 33
“This suppresses proactivation signals by activating ligands (B7-1 and B7-2) and induces the enzyme Inoleamine 2,3-dioxygenase (IDO) which impairs Ca2+ mobilization and suppresses T cell activation, ultimately altering IL-2 production and other effector functions in T cells [51,54,55].”
BackgroundYu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 34
“It has been shown in some studies CTLA-4 disrupts the formation of zeta-associated protein of 70 kD (Zap70) microclusters (Schneider et al., 2008), while others propose different mechanisms (Calvo et al.”
BackgroundModulation of CTLA-4 and GITR for Cancer Immunotherapy
Avogadri, F., Yuan, J. D., Yang, A. S., Schaer, D., & Wolchok, J. D. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_49 · Cited by 33
“This block in IS formation applies also to ZAP-70 microclusters which are needed to maintain calcium flux and downstream events in TCR signaling (Bunnell et al. 2002; Schneider et al. 2008).”
BackgroundLiu, H., Schneider, H., Recino, A., Richardson, C. A., Goldberg, M. W., & Rudd, C. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.015 · Cited by 33
“10 cells were cultured as previously described (Liu et al., 2010; Raab et al., 1999; Schneider et al., 2008).”
MethodSelf-citationKanda, Y., Okazaki, T., & Katakai, T. (2021) · Cancers · doi:10.3390/cancers13184616 · Cited by 36
“CTLA-4-mediated transient contact with APCs inhibits the formation of ZAP70 microclusters in T cells, leading to the suppression of IL-2 production and cell proliferation [75].”
BackgroundInfluentialRush, C. M., Millington, O. R., Hutchison, S., Bryson, K. J., Brewer, J. M., & Garside, P. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03124.x · Cited by 28
Inhibitory and Regulatory Immune Synapses
Eissmann, P., & Davis, D. M. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-03858-7_4 · Cited by 26
“Engagement of these receptors negatively regulates signalling through the T-cell antigen receptor (Chouaib et al. 2002; Peggs et al. 2008; McMahon and Raulet 2001; Snyder et al. 2002; Ugolini and Vivier 2000; van Bergen et al. 2004) and influences the supramolecular organization of the IS (Dietrich et al. 2001; Fourme…”
BackgroundInfluentialPoirier, N., Blancho, G., & Vanhove, B. (2010) · Immunotherapy · doi:10.2217/imt.10.57 · Cited by 25
T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels
Messmer, J. M., Thommek, C., Piechutta, M., Venkataramani, V., Wehner, R., Westphal, D., Schubert, M. C., Mayer, C. D., Effern, M., Berghoff, A. S., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.003 · Cited by 26
Blockade of CTLA-4 Decreases the Generation of Multifunctional Memory CD4+ T Cells In Vivo
Rudolph, M., Hebel, K., Miyamura, Y., Maverakis, E., & Brunner-Weinzierl, M. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003381 · Cited by 27
Liu, H., Thaker, Y. R., Stagg, L., Schneider, H., Ladbury, J. E., & Rudd, C. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424846 · Cited by 24
“Weiss, University of California, San Francisco) were cultured as described (51).”
MethodSelf-citationWang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 25
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 22
Liu, H., Purbhoo, M. A., Davis, D. M., & Rudd, C. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909112107 · Cited by 18
“Although the inhibitory coreceptor CTLA-4 potentially inhibits ZAP-70 cluster formation (28), whereas very late antigen 4 (VLA-4) can stabilize their presence (29).”
BackgroundMethodSelf-citationFish Uses CTLA-4 Immune Checkpoint to Suppress mTORC1-Controlled T-Cell Glycolysis and Immunity
Zhang, J., Wei, X., Zhang, Q., Jiao, X., Li, K., Geng, M., Cao, Y., Wang, D., Cheng, J., & Yang, J. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300599 · Cited by 17
An Integrative Network Modeling Approach to T CD4 Cell Activation
Martínez-Méndez, D., Villarreal, C., Mendoza, L., & Huerta, L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00380 · Cited by 18
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 23
The nephrotoxicity of new immunotherapies
Sury, K., & Perazella, M. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1613888 · Cited by 17
Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse
González, P. A., Carreño, L. J., Céspedes, P. F., Bueno, S. M., Riedel, C. A., & Kalergis, A. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/450291 · Cited by 17
Pérez‐Quintero, L., Abidin, B. M., & Tremblay, M. L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1364778 · Cited by 17
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 21
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions
Fathi, M., Razavi, S., Sojoodi, M., Ahmadi, A., Ebrahimi, F., Namdar, A., Hojjat‐Farsangi, M., Gholamin, S., & Jadidi‐Niaragh, F. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2160703 · Cited by 15
“Furthermore, CTLA-4 can disrupt the central Supramolecular Cluster (cSMAC) within the immunological synapse and inhibit proximal TCR signaling by inhibiting ZAP-70 to regulate the threshold of T cell activation [74,75].”
BackgroundAhmed, A., Mukherjee, S., & Nandi, D. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02902.x · Cited by 15
Liao, Z., Lv, X., Liu, S., He, Z., Chen, S., Wang, L., Li, W., & Li, Y. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12850 · Cited by 15
Put in a “Ca2+ll” to Acute Myeloid Leukemia
Lewuillon, C., Laguillaumie, M.-O., Quesnel, B., Idziorek, T., Touil, Y. S., & Lemonnier, L. (2022) · Cells · doi:10.3390/cells11030543 · Cited by 18
Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach
Azarov, I., Helmlinger, G., Kosinsky, Y., & Peskov, K. V. (2022) · Frontiers in Applied Mathematics and Statistics · doi:10.3389/fams.2022.993581 · Cited by 14
“Such simulation results are also fully consistent with effects observed in both in vitro and in vivo studies [5, 42].”
ResultMining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity
Penafuerte, C., Pérez‐Quintero, L., Vinette, V., Hatzihristidis, T., & Tremblay, M. L. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_68 · Cited by 14
“In addition, CTLA-4 stimulated cells showed more motility, suggesting the CTLA-4 signals inhibit the formation of a mature immunological synapse (IS) and maintain T cells in a naive phenotype by inhibiting early kinase activity (Schneider et al. 2008).”
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
Васильевна, Б. А., Efimov, G. A., Drutskaya, M. S., & Недоспасов, С. А. (2015) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2015-5-395-406 · Cited by 16
“Обратная интернализация CTLA-4 регулируется такими молекулами, как AP-1, AP-2 (адаптерные белки клатрина, не путать с транскрипционными факторами) [69] и киназой Rlk.”
The Role of Costimulatory Pathways in Transplant Tolerance
Uehara, M., & McGrath, M. M. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.10.009 · Cited by 14
Lin, W., Fan, Z., Suo, Y., Deng, Y., Zhang, M., Wang, J. O., Wei, X., & Chu, Y. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.76 · Cited by 14
Current advances and future directions of combined ICIs and TILs in solid tumors
Wang, Y., Ding, Q., & Wei, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218145 · Cited by 14
Rôle du microbiote intestinal dans la réponse aux thérapies anti-tumorales
Vétizou, M., Daillère, R., & Zitvogel, L. (2017) · Biologie Aujourd hui · doi:10.1051/jbio/2017009 · Cited by 10
Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis
Nagai, K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.584382 · Cited by 10
“CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death 1; TIM-3, T-cell immunoglobulin 3; TIGIT, T-cell immunoglobulin and ITIM domain; LAT, linker for activation of T cells; TCR, T-cell receptor; ZAP-70, ζ-associated protein of 70 kD; SLP-76, SH2-binding leukocyte phosphoprotein of 76 kD; ITI…”
BackgroundInfluentialWatari, K., Konnai, S., Okagawa, T., Maekawa, N., Sajiki, Y., Kato, Y., Suzuki, Y., MURATA, S., & Ohashi, K. (2021) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0552 · Cited by 10
“The binding of CTLA-4 to CD80/86 transmits an inhibitory signal that suppresses T-cell functions [3, 31, 32].”
BackgroundTargeting CD28 to prevent transplant rejection
Yeung, M. Y., Najafian, N., & Sayegh, M. H. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.863875 · Cited by 11
The Role of Cell Growth-Related Gene Copy Number Variation in Autoimmune Thyroid Disease
Guan, Y., Liu, L., Jia, Q., Jin, X. Y., Pang, Y., Meng, F., Zhang, X., & Shen, H. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01880-7 · Cited by 9
Mechanistic Insights into the Inhibition of a Common CTLA-4 Gene Mutation in the Cytoplasmic Domain
Xu, J., Zhang, Y., Shen, L., Du, L., Xue, H., Wu, B., & OuYang, B. (2024) · Molecules · doi:10.3390/molecules29061330 · Cited by 8
“Numerous intracellular proteins have been reported to engage in binding interactions with the Y 201 VKM motif [13–15].”
BackgroundInborn errors of immunity associated with defects of self‐tolerance checkpoints: The CD28 family
Rush‐Kittle, J., Gámez-Díaz, L. Y., & Grimbacher, B. (2022) · Pediatric Allergy and Immunology · doi:10.1111/pai.13886 · Cited by 7
Guo, W.-J., Liu, S., Zhang, X., Chen, Y., Qian, R.-L., Zou, Z., Chen, X., & Luo, P. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s148443 · Cited by 6
Tulsian, K., Thakker, D., & Vyas, V. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141364 · Cited by 6
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
CD5 Deficiency Alters Helper T Cell Metabolic Function and Shifts the Systemic Metabolome
Whitley, K. V., Freitas, C. M. T., Moreno, C. M., Haynie, C., Bennett, J., Hancock, J. C., Cox, T. D., Pickett, B. E., & Weber, K. S. (2022) · Biomedicines · doi:10.3390/biomedicines10030704 · Cited by 5
The adverse kidney effects of cancer immunotherapies
Saly, D. L., & Perazella, M. A. (2018) · Journal of Onco-Nephrology · doi:10.1177/2399369318808806 · Cited by 4
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Tentori, L., & Navarra, P. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_10 · Cited by 2
“CTLA-4 is, instead, up-regulated on the surface of activated T cells in response to TCR/CD28 costimulation [3].”
BackgroundInfluentialImmune Checkpoint Inhibitors - New Insights and Recent Progress
Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2
Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma
Festino, L., Vanella, V., Strudel, M., & Ascierto, P. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00007-1 · Cited by 3
Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Huang, J., & Huang, J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.107435 · Cited by 3
Wang, Y., Mei, X., Zhong, J., Wang, J., Cao, J., Zheng, S., Qi, D., & Wang, Z. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04297-5 · Cited by 1
Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_11 · Cited by 2
Cytotoxic T Lymphocytes and Their Granzymes: An Overview
Noonan, J., & Murphy, B. M. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_5 · Cited by 2
Metadata
- Authors
- Schneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E.
- Affiliations
- University of Cambridge (GB)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Rudd, Christopher E.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2007-12-21
- Volume
- 38
- Issue
- 1
- Pages
- 40-47
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- PMC
- PMC5580795
- OpenAlex
- W2039460569
- Cited by
- 116
- References
- 39
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 12 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 14 · 2017: 8 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 7 · 2012: 3
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, ZAP-70, immunological synapse, T cell activation, calcium mobilization, IL-2 production, T cell motility, T cell co-receptors, stop signal
- MeSH terms
- Animals, Antigen-Presenting Cells, Antigens, Differentiation, Calcium, Cell Adhesion, Cell Communication, Cell Movement, Humans, Lymphocyte Activation, T-Lymphocytes, Antigens, CD, Mice, ZAP-70 Protein-Tyrosine Kinase, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.